Synchronization of estrus in yearling beef heifers with melengestrol acetate and prostaglandin F(2alpha)

This study was designed to test the efficacy of melengestrol acetate (MGA) in combination with prostaglandin F(2alpha) (PGF(2alpha)) in synchronizing estrus in cyclic and noncyclic heifers. One hundred thirty-one cyclic and prepubertal crossbred heifers were randomly assigned to three treatment groups: Controls (n = 43); MGA (0.5 mg/d for 7 d) and PGF(2alpha) (25 mg i.m. on Day 7; n = 44); and PGF(2alpha) (25 mg i.m. on Day 7; n = 44). Observations for estrus were made at 6-n intervals throughout the 7-d treatment period followed by a 34-d artificial insemination breeding season. A greater percentage (P < 0.05) of MGA-PGF(2alpha) noncyclic heifers showed behavioral estrus (91%) than did Control (67%) or PGF(2alpha) heifers (61%) during the 34-d artificial insemination period. There was no difference (P > 0.05) between synchronization rates of the MGA-PGF(2alpha) heifers and PGF(2alpha) heifers 7 d after PGF(2alpha) administration. The percentage of control animals in estrus during the first 25 d of the breeding season did non differ from the synchronized rates of MGA-PGF(2alpha) and PGF(2alpha) heifers (P > 0.05). Conception rates (heifers pregnant/heifers inseminated) did not differ (P > 0.05) for cyclic or prepubertal heifers among Control, MGA-PGF(2alpha) or PGF(2alpha) heifers. Though conception rates did not differ, there was a trend toward lowered conception rates in MGA-PGF(2alpha) heifers.     

Synchronization of estrus in beef heifers with a norgestomet implant and prostaglandin F2alpha

In a 5-year study (1973-1977), 281 cycling beef heifers were treated with a 7-day norgestomet (SC21009) ear implant and an intramuscular injection of prostaglandin F(2alpha) (PGF(2alpha)) at the time of implant removal or 24 hr before implant removal. Percentages of heifers in estrus by 36, 48, 60, 72, and 120 hr after implant removal were 32.4, 52.7, 71.6, 80.1, and 93.2, respectively. Onset of estrus occurred an average of 49.8 +/- 4.7 hr after treatment. Percentages of heifers in estrus 36 hr after treatment were 5.7 and 51.7 for those with a corpus luteum and those without a corpus luteum (or determined regressing by palpation) at implant removal, respectively. When PGF(2alpha) was injected 24 hr before implant removal, 55% of the heifers were in estrus by 36 hr after implant removal compared to 30% when PGF(2alpha) was injected at the time of implant removal; however, by 60 hr after implant removal the difference was 76% vs. 71%. First-service conception rates for synchronized and nonsynchronized heifers were 62.2% and 59.6%, respectively. During 1976 and 1977 heifers were checked for estrus every 4 hr and inseminated 2, 6, 10, 14, 18, 22, 26, or 30 hr after first detected to be in standing estrus. Conception rate was not significantly affected by time of insemination but tended to be higher for heifers bred 26 and 30 hr after first being detected in standing estrus (78.9% and 70.0% vs. average 59.2%). Treatment with a 7-day norgestomet implant plus a single injection of PGF(2alpha) 24 hr before or at implant removal appears to be a practical technique for synchronizing estrus in cycling heifers without affecting conception.     

Synchronization of estrus in suckled postpartum beef cows with melengestrol acetate and PGF2alpha

A total of 402 two suckled postpartum beef cows at 2 locations (CSU and ECRC) were utilized in 3 trials to evaluate the effectiveness of a combination melengestrol acetate (MGA)-PGF2alpha estrus synchronization system in spring-calving cows. The cows were allocated by days post partum, body condition score (1 = emaciated; 9 = obese), sire breed, and dam age at the beginning of treatment to 1 of 2 treatments within location and trial: MGA-PGF2alpha (0.5 mg MGA/head/d for 14 d with 25 mg of PGF2alpha injected 17 d after MGA withdrawal), and unsynchronized controls. All cows were observed for estrus at 12-h intervals for at least 5 d post injection. Cows observed in standing estrus were inseminated 12 to 18 h later. There was a location effect on response to treatment that was attributed to differences in body condition score between locations so data were analyzed within a location. Body condition score at the CSU location was 5.7 compared with 4.0 at the ECRC location. The CSU MGA-PGF2alpha treated cows had higher (P < 0.05) 5-day estrus and 5-d pregnancy rates (78.6 and 61.0%, respectively) than the CSU controls (11.1 and 6.9%, respectively). Similar results for 5-d estrus and pregnancy rates but of decreased magnitude were also observed for the ECRC MGA-PGF2alpha treated (31.6 and 21.4%, respectively) cows compared with that of the ECRC controls (11.9 and 8.5%, respectively). The CSU MGA-PGF2alpha treated cows had higher (P < 0.05) 25- and 60-d pregnancy rates (82.5 and 94.8%) than the CSU controls (65.3 and 87.5%). The 25- and 60-d pregnancy rates were similar between the ECRC MGA-PGF2alpha treated cows and ECRC control cows. The MGA-PGF2alpha estrus synchronization system appears to contribute to pregnancy early in the breeding season in postpartum beef cows, although its effectiveness is limited by cow body condition.     

Comparison of timed insemination with insemination at estrus following synchronization of estrus with a MGA-prostaglandin system in beef heifers

Three trials utilizing 231 beef heifers were conducted in 1993 to determine if a timed insemination would result in similar synchronized pregnancy rates as insemination by estrus following synchronization of estrus using the 14-d MGA-prostaglandin system. All heifers were fed 0.5 mg MGA/h/d fof 14 d and given a 25 mg injection of PGF(2)alpha im 17 d after the final day of MGA feeding. Heifers in Group 1 (timed AI treatment) were inseminated at 72 h after the prostaglandin injection independent of whether or not they were observed in estrus. Heifers in Group 2 (AI by estrus) were inseminated 12 to 18 h after the onset of estrus. Since the trial was a significant source of variation for synchronized pregnancy rate, the effect of treatment on pregnancy rate was analyzed for each trial. Synchronized pregnancy rates in Trials 2 and 3 were similar in both treatment groups; 37 vs 35% and 61 vs 58% for the timed AI vs AI by estrus (Groups 1 and 2) in Trials 2 and 3, respectively. In both of these trials the degree of estrous synchrony was high. In Trial 1, the synchronized pregnancy rate in heifers that were time-inseminated was significantly lower than that of heifers that were inseminated by estrus (29 vs 57%). The lower synchronized pregnancy rate of Group 1 (timed AI) heifers in Trial 1 appeared to be due to the low degree of estrous synchrony in this trial. Our results indicate that using timed insemination with the 14-d MGA-prostaglandin system will give similar synchronized pregnancy rates as inseminating by estrus in groups of beef heifers where the degree of synchrony is high. However, in heifers where the degree of estrous synchrony is low, a timed insemination reduces synchronized pregnancy rates.     

Synchronization of estrus in virgin beef heifers using melengestrol acetate and PGF2alpha: an efficacy comparison of cloprostenol and dinoprost tromethamine

This study compared the efficacy of two sources of PGF2alpha on the reproductive performance of virgin beef heifers, after synchronization of estrus using melengestrol acetate (MGA) and PGF2alpha. Angus-based heifers (n = 1002) in five herds were fed 0.5 mg per head per day of MGA for 14 days. Nineteen days after the last day of MGA feeding, heifers were randomly assigned to receive (i.m.) either 0.5 mg cloprostenol (n = 504; Estrumate, E) or 25 mg dinoprost tromethamine (n = 498; Lutalyse, L) as a source of exogenous PGF2alpha. Heifers were observed twice daily for 5 days for signs of estrus and artificially inseminated 8-12 h later, except in herd A, wherein animals not detected in estrus by 80 h after PGF2alpha were mass-mated and no longer monitored for signs of estrus. Estrumate and Lutalyse were equally (P > 0.1) effective among all response variables evaluated, including estrus response (E, 89% and L, 86%), conception rate (E, 67% and L, 67%), and synchronized pregnancy rate (E, 61% and L, 57%). Synchrony of estrus was not affected (P > 0.1) by PGF2alpha source, and peak estrus response occurred 60 h post-PGF for both treatments. Conception rate to timed insemination was not different (P > 0.1) among Estrumate- and Lutalyse-treated heifers within herd A (14%, 4/28 and 7%, 2/29, respectively). Herd had a significant (P < 0.05) effect on all indicators of reproductive performance. Conception rates within herds A and D were influenced by technician (P < 0.05), however, this effect was balanced across treatments and no treatment by technician interaction was detected. In conclusion, when administered 19 days after a 14-day MGA feeding period, cloprostenol and dinoprost tromethamine are equally efficacious for synchronous induction of a fertile estrus in virgin beef heifers.     

Synchronization of estrus in suckled postpartum beef cows with melengestrol acetate, 48-hour calf removal and PGF2alpha

One hundred and sixty-five suckled postpartum beef cows were utilized to evaluate the effectiveness of 2 estrus synchronization systems for the initiation and synchronization of estrus. The treatment groups consisted of 1) melengestrol acetate (MGA)-PGF2alpha (cows were given 0.5 mg MGA/head/day for 14 d with 25 mg PGF2alpha injected 17 d after the last day of MGA administration); 2) MGA-48-h calf removal (CR)-PGF2alpha (cows were given 0.5 mg MGA/head/day for 14 d with 48-h calf removal starting on the second day after completion of the MGA regimen plus 25 mg PGF2alpha administered 17 d after the last day of MGA); and 3) unsynchronized controls. Cows were assigned to treatments by the numbers of days post partum, body condition, age, and breed of sire. The cows were observed for estrus at 12-h intervals for 5 d after PGF2alpha administration and were artificially inseminated 12 to 18 h after the observed estrus. Both the MGA-PGF2alpha and MGA-CR-PGF2alpha treatments (64.8 and 61.8%) had greater (P < 0.05) 5-d estrus rates than the control treatments (34.5%). The synchronized pregnancy rate was greater (P < 0.05) for the MGA-CR-PGF2alpha than the control treatment.(52.7 vs 30.9%, respectively). The MGA-CR-PGF2alpha cows had a higher 25-d pregnancy rate than either the MGA-PGF2alpha (P < 0.05) or control cows (P < 0.08). Of the anestrous cows at the beginning of treatment, more MGA-CR-PGF2alpha (P = 0.1) and MGA-PGF2alpha cows were cyclic posttreatment than control cows (58.7 and 55.1 vs 44.7%, respectively), suggesting that treatment initiated estrous cycles in only a small number of the anestrous cows. Both MGA-PGF2alpha and MGA-CR-PGF2alpha treatments appear to be effective methods of synchronizing estrus in suckled postpartum beef cows. However, MGA-CR-PGF2alpha was more effective in establishing pregnancy earlier in the breeding season than MGA-PGF2alpha.     

Synchronization of estrus in cyclic beef heifers with the prostaglandin analog alfaprostol

Seventy-eight Hereford-Angus crossbred heifers were injected intramuscularly twice with 6 mg of alfaprostol^b in 6 ml of propylene glycol. On each representative day of a 20-day estrous cycle (estrus = Day 0), either three or four heifers received their first injection. The second injection was given 12 days after the first, regardless of the response to the first injection. Thirty-nine heifers were not treated. The first alfaprostol injection reduced serum progesterone to less than 1 ng/ml in all heifers injected after Day 4. A total of 79.5% ($\text{62}\text{78}$) of the heifers exhibited estrus by five days after the first injection. Average interval from injection to estrus was 63 hours. The second injection occurred on Days 6 through 16 for all but one heifer, with 75.6% ($\text{59}\text{78}$) falling on Days 8 through 11 of the estrous cycle. Estrus was detected in 93.6% ($\text{73}\text{78}$) of the heifers within five days after the second injection, with an average interval to estrus of 66 hours.Day of cycle at second injection did not affect the interval to estrus. Conception occurred in 79.4% ($\text{58}\text{73}$) of the heifers inseminated in the five days after the second injection. Occurrence of estrus and conception was no different in treated heifers after five days of the insemination period than in nontreated heifers after 21 days of the insemination period, where 94.9% ($\text{37}\text{39}$) were observed in estrus and 83.8% ($\text{31}\text{37}$) conceived. Overall percent conception for a 55-day insemination period was 89.7 ($\text{70}\text{78}$) for treated and 87.2 ($\text{34}\text{39}$) for nontreated heifers. Day of cycle at first or second injection did not affect conception after the second injection. Some signs of estrus were observed in 11 of the 16 heifers injected before Day 5.A second trial to determine if alfaprostol induced luteolysis early in the cycle was conducted. Twenty purebred Angus, Hereford, or Simmental heifers received either one or two injections of alfaprostol on either Day 1, 2, 3, or 4. Only five heifers showed any signs of estrus, and the three that were inseminated did not conceive. Subsequent cycle length indicated that luteolysis occurred in only one heifer.Data suggest that alfaprostol is an effective luteolytic agent in cyclic beef heifers after Day 4 and that two injections 12 days apart will effectively synchronize estrus in heifers when distributed throughout the cycle at the first injection without affecting conception rate.     

Synchronization of estrus after treatment with Luprostiol in beef cows and in beef and dairy heifers

Four trials were conducted to study synchronous estrous response in beef cows and in beef and dairy heifers to Luprostiol (13, thia-PG-F(2)alpha analog) in comparison with other prostaglandin products. In Trial 1, 60 virgin beef heifers were observed for estrus for 5 d and artificially inseminated. Heifers not observed in estrus within 5 d were randomly assigned to receive 15 mg Luprostiol or 25 mg Lutalyse. In Trial 2, 75 multiparous, lactating beef cows were randomly assigned to receive either 15 mg Luprostiol, 25 mg Lutalyse or 500 mcg Estrumate. All cows received a second injection of the respective treatment 11 d later. In Trial 3, 96 multiparous, lactating beef cows were randomly assigned to receive 15 mg Luprostiol or 25 mg Lutalyse. All cows received a second injection of the respective treatment 11 d later. In Trial 4, virgin dairy heifers were palpated per rectum. Seventy-seven heifers with a palpable corpus luteum (CL) were randomly assigned to receive 15 mg Luprostiol or 500 mcg Estrumate. In all trials animals were artificially inseminated 12 h following observed estrus. Estrous response during the 5-d synchronized period was 44% for Luprostiol and 42% for Lutalyse treated heifers in Trial 1. It was 52, 56 and 60%, respectively, for Luprostiol, Lutalyse and Estrumate treated cows in Trial 2; 23% for Luprostiol and 19% for Lutalyse treated cows in Trial 3; and 68% for Luprostiol and 70% for Estrumate treated heifers in Trial 4. Treatment with Luprostiol results in a similar synchronous estrous response as with the other prostaglandin products used in these studies.     

Fixed-time insemination in peripuberal,lightweight replacement beef heifers after estrus synchronization with PGF2alpha and GnRH

Estrus synchronization contributes to optimizing the use of time, labor, and financial resources by shortening the calving season, in addition to increasing the uniformity of the calf crop. We determined whether acceptable pregnancy rates could be achieved after synchronization of ovulation and fixed-time artificial insemination (AI) in peripuberal replacement beef heifers using gonadotropin-releasing hormone (GnRH) and PGF2alpha. Crossbred heifers from two herds (MH, n=239; SS, n=330) were wintered at a single location. After a prebreeding examination revealed that 55 heifers had a reproductive tract score (RTS) of 1 (infantile reproductive tracts), they were culled and the remaining heifers were assigned randomly to one of three treatment groups: administration of 25mg PGF2alpha i.m. on Days -12 and 0 followed by estrus detection and insemination between 10 and 14 h after an observed estrus (Control; n=173); administration of 100 microg GnRH i.m. on Day -6, followed by 25 mg PGF2alpha i.m. on Day 0, then fixed-time AI and administration of 100 microg GnRH i.m. on Day +2 (GPG; n=172); and, treatment as for group GPG in addition to administration of 100 microg GnRH i.m. on Day -12 (GGPG; n=169). Bulls were introduced 10 days after AI for 60 days to breed heifers which did not conceive after AI (clean-up bulls). On Days -12, -6, and 0 transrectal ultrasonography was used to monitor ovarian structures in a subset of heifers (30 per treatment). At 30-35 days after AI, ultrasound was used to determine the presence of a viable fetus. Presence of a fetus and stage of pregnancy were determined via palpation per rectum 61-63 days after the conclusion of the breeding season. Heifers in the MH herd (309+/-1.9 kg) were heavier (P<0.001) than those in the SS herd (283+/-1.7 kg) at initiation of the breeding season. Synchronized pregnancy rates were greater (P<0.05) in GGPG (25.4%) and GPG (22.1%) than Control (12.7%) heifers. Pregnancy rates were 9, 21, 32, or 31% for heifers with RTS of 2, 3, 4, or 5, respectively. The average diameter of 22 follicles induced to ovulate in heifers treated with GnRH (GPG and GGPG treatments) was 14.2+/-0.8 mm (range=10.0-23.6 mm). In conclusion, a fixed-time ovulation synchronization program using GnRH and PGF2alpha improved pregnancy rates in peripuberal, lightweight replacement beef heifers.     

Synchronization of estrus in early diestral dairy heifers with Prostaglandin F(2)alpha and estradiol benzoate

Following observation of estrus, 134 Holstein heifers were given injections of Prostaglandin F(2)alpha (PGF(2)alpha) between Days 5 and 10 of their cycle (estrus = Day 0). They were then randomly assigned to either a group receiving 400 mug of estradiol benzoate (E(2)B) 40 h or maintained as controls. Heifers observed in estrus within 120 h of PGF(2)alpha administration were inseminated (approximately 12 h after initial observation of estrus). Blood samples for progesterone determination were drawn from the coccygeal vein on Days 15 and 21 after insemination. Pregnancy was confirmed by palpation per rectum between Days 5.0 and 60 post insemination. When control and treated heifers were compared it was found that a higher percentage of heifers treated with E(2)B exhibited estrus after PGF(2)alpha, but there had been no effect on subsequent progesterone concentrations or pregnancy rates.     

Comparison of Melengestrol Acetate-Prostaglandin F(2)alpha to Syncro-Mate B for estrus synchronization in beef heifers

Three hundred and ten yearling heifers of various breeds were used in five trials to compare two estrus synchronization treatments. Treatment 1 consisted of Melengestrol Acetate-Prostaglandin F(2)alpha (MGA-PGF(2)alpha). Heifers were fed 0.5 mg MGA/head/d for 14 to 16 d. Sixteen or 17 d after the final MGA feeding, heifers were injected i.m. with 25 mg PGF(2)alpha. Treatment 2 consisted of Syncro-Mate B (SMB). Heifers were given a 9-d norgestomet implant plus an injection containing 3 mg norgestomet and 5 mg estradiol valerate i.m. at implant insertion. Heifers were observed for estrus at 6-h intervals for 120 h after the end of treatments and were artificially inseminated 12 to 18 h after observed estrus. Heifers synchronized with MGA-PGF(2)alpha and SMB had a similar (P > 0.10) estrous response (83.4 vs 90.2%) and a similar (P > 0.10) degree of synchrony (71.8 vs 79.0%) following treatment. However, the synchronized conception rate (68.7 vs 40.6%) and the synchronized pregnancy rate (57.3 vs 36.6%) were higher (P < 0.01) in MGA-PGF(2)alpha than SMB heifers. Breeding season pregnancy rates were similar in both treatment groups. Heifers in both groups that were classified as cycling prior to initiation of treatment had improved reproductive performance following synchronization compared with those classified as noncycling. Based on higher synchronized conception and pregnancy rates and lower labor requirements and drug costs, the MGA-PGF(2)alpha system appears to be a better method to synchronize estrus in beef heifers than the SMB system.     

Change in morphology of corpora lutea, central luteal cavities and steroid secretion patterns of postpartum suckled beef cows after melengestrol acetate with or without prostaglandin F2alpha

Change in morphology of the corpus luteum (CL) and patterns of progesterone and estradiol secretion after treatment with melengestrol acetate (MGA) were monitored in postpartum beef cows. Twenty Angus cows were randomly assigned to MGA or MGA + prostaglandin F(2alpha) (PGF) treatments. All cows were fed 0.5 mg of MGA per cow per day for 14 d. The MGA-treated cows (n = 10) were allowed to return to estrus spontaneously at the second estrus after withdrawal of MGA from the feed. The MGA + PGF-treated cows (n = 10) received an injection containing 25 mg of PGF(2alpha) 17 d after the last feeding of MGA. Cycle 1 was defined as the first luteal phase after MGA feeding and Cycle 2 represented the subsequent cycle or luteal phase after PGF. Blood sampling and transrectal ultrasonography of the ovaries was done daily through the completion of 2 estrous cycles upon removal of MGA from the feed. Blood samples were analyzed for plasma progesterone and estradiol concentrations. Area of CL and fluid-filled cavities within each CL were determined by ultrasonography. Concentrations of progesterone and area of CL were similar between cycles and treatments. Estradiol concentrations were higher (P < 0.05) in Cycle 2 than in Cycle 1. Fluid-filled cavities were larger (P < 0.001) in Cycle 1 than in Cycle 2 for both mid-luteal (Days 5 to 9) and late-luteal (Days 10 to 14) phases. Multiple CL (2 or more during 1 cycle) were observed in 5 cows. Progesterone concentrations and total area of luteal tissue did not change with respect to treatment or cycle, but CL morphology was altered in the first cycle after MGA treatment. Of the 19 cows that ovulated after withdrawal of MGA, 3 experienced a short luteal phase. These data characterize changes that occur among cows that are fed melengestrol acetate during the postpartum period and enhance observations from prior studies regarding MGA use.     

Effect of prostaglandin F(2)alpha at insemination on sperm cell numbers and pregnancy rate in beef cattle

Fourteen cycling, nonlactating, multiparous beef cows were artificially inseminated (AI) 10 to 12 h after the onset of natural estrus. One unit of frozen-thawed semen containing 100 x 10(6) total sperm cells was deposited into the body of the uterus. Immediately after AI, alternating cows were injected i.m. with either 25 mg (5 ml) of prostaglandin F(2)alpha (PGF) or 5 ml of 0.9% saline-benzyl alcohol control solution. Cows were slaughtered 16 +/- 1 h post AI, oviducts were retrieved, segmented into thirds (upper, middle and lower) and flushed with 1 ml of 0.2% gluteraldehyde in phosphate buffered saline. The number of sperm cells was counted using a phase contrast microscope. There were no right or left side effects (P=0.61) on the number of sperm cells recovered per oviduct within cow (389 vs 553; average SEM = 219). PGF had no effect (P=0.77) on the number of sperm cells recovered per oviduct (642 vs 300; average SEM = 231 for PGF and control females, respectively). More sperm cells were recovered from the lower third segment (P<0.05) compared with the middle and upper segments. Ovulation tended to affect (P=0.10) the number of sperm cells recovered per oviduct (742 vs 200; average SEM = 231). Additionally, 114 beef females (68 Angus x Hereford heifers and 46 Chianina crossbred postpartum suckled cows) were treated as described above following AI at natural estrus with 20 x 10(6) motile sperm cells. Pregnancy rates did not differ significantly in heifers (70.6 vs 58.8%) or in Chianina cows (34.8 vs 52.2%) for control and PGF-treated females, respectively. Overall, pregnancy rates were identical between control and PGF-treated females at 56.1%. In this study, PGF treatment immediately following AI in beef cattle had no effect on the number of sperm cells in the oviducts or on the pregnancy rate.     

Doses of prostaglandin F(2)alpha effective for induction of estrus in goats

A total of 11 cycling does weighing between 24 and 50 kg were injected with varying dosages of prostaglandin F(2)alpha (PGF(2)alpha) between 7 and 10 days into each estrous cycle. Five injections each of 1.25, 2.5, 5.0, or 7.5 mg PGF(2)alpha were alternated with five injections of 1.0 ml saline. Saline treated does served as controls. All does were teased twice daily with a buck and observed for signs of estrus for 5 days post-injection. Daily systemic concentrations of progesterone (P(4)) were determined by radioimmunoassay. The mean (+/- S.E.) hours from injection to estrus was 47 +/- 3.3, 42 +/- 4.3, 44 +/- 8.5, and 43 +/- 5.5 for does receiving 1.25, 2.5, 5.0, and 7.5 mg PGF(2)alpha, respectively. None of the does receiving saline exhibited estrus in the 5-day post-injection observation period. Mean (+/- S.E.) concentrations of systemic P(4) in all does on the day of injection was 4.22 +/- 0.45 ng/ml. Concentrations 24 hours post-injection were 0.21 +/- 0.02, 0.15 +/- 0.05, 0.17 +/- 0.04, 0.16 +/- 0.04, and 4.5 +/- 1.36 ng/ml for does receiving 1.25, 2.5, 5.0, and 7.5 mg PGF(2)alpha, and 1.0 ml saline, respectively. The results suggested that 1.25 mg PGF(2)alpha was effective for induction of estrus in the cycling goat.     

Efficacy of either a single or split treatment of PGF2alpha after a 14 day melengestrol acetate treatment to synchronize estrus and induce luteolysis in Bos indicus x Bos taurus heifers

Two experiments evaluated a modified delivery of prostaglandin F2alpha (PGF2alpha) after a melengestrol acetate (MGA) treatment in Angus and Bos indicus x Bos taurus (BI) heifers. Experiment 1 was replicated three times with yearling BI heifers (n = 695). Heifers received MGA (0.5 mg head(-1) day(-1)) for 14 days. In Replications 1 and 2, heifers received either 25 mg of PGF2alpha im 19 days after MGA (single) or 12.5 mg of PGF2alpha im 19 and 20 days after MGA (split). In Replication 3, heifers received the same treatments, with PGF2alpha initiated either 18 or 19 days after MGA. Estrus was detected for 72 h after PGF2alpha, with AI commencing 8-12 h after a detected estrus. Heifers not observed in estrus by 72 h were timed-AI concomitant with GnRH (100 microg im). Heifers from Replication 2 (n = 146) had blood samples collected at the initial PGF2alpha and at timed-AI to determine corpus luteum (CL) regression by evaluating plasma progesterone concentrations. The interval from MGA withdrawal to PGF2alpha did not have a significant effect on any variable in Replication 3 and there were no treatment by replication effects for any variables, therefore data were pooled. Modifying the PGF2alpha treatment from a single treatment to two treatments on consecutive days increased (P < 0.05) 72 h estrous response (43.2% versus 50.1%), timed-AI (23.9% versus 33.5%) and total-AI pregnancy rates (34.5% versus 42.5%), and CL regression (79.1% versus 92.5%), respectively. In Experiment 2, yearling Angus (n = 66) and 2-year-old BI (n = 68) heifers were synchronized as per Experiment 1 (with the initial PGF2alpha 19 days after MGA). Neither breed nor PGF2alpha treatment effected (P > 0.05) 72 h estrous response, total-AI pregnancy rate, or CL regression rate. In conclusion, treating yearling BI heifers with split treatments of PGF2alpha (given on two consecutive days) improved estrous response and pregnancy rates by increasing PGF2alpha-induced luteolysis.     

Conception rates in repeat-breeders and dairy cattle with unobserved estrus after prostaglandin F(2) alpha and gonadotropin-releasing hormone

In Experiment 1, cows with a history of at least two previous unsuccessful inseminations were allocated to four groups. At the repeated estrus (third or greater service), some of the cows were inseminated according to the a.m.-p.m. rule (Controls, n = 83), or received i.m. 100 mug gonadotropin-releasing hormone (GnRH, n = 32) within 30 sec after insemination. Ovaries of the remaining cows to be treated were palpated during the anticipated ensuing luteal phase to determine the presence of a corpus luteum. Cows found to have luteal tissue received i.m. 25 mg prostaglandin F(2)-alpha (PGF(2)-alpha) and were inseminated after detected estrus or at 72 and 96 h after PGF(2)-alpha in the absence of estrus. Cows given PGF(2)-alpha either received no further treatment (PGF(2)-alpha, n = 40) or were given i.m. 100 mug GnRH (PGF(2)-alpha + GnRH, n = 29) after insemination or at 72 h after PGF(2)-alpha in the absence of estrus. Conception rate of control cows (39%) was similar to that of cows given PGF(2)-alpha (40%) or PGF(2)-alpha + GnRH (43%), but it tended to be lower (P = 0.13) than that of cows given only GnRH at insemination (54%). In Experiment 2, cows with unobserved estrus and diagnosed not pregnant (palpation) were palpated to detect a corpus luteum. Cows with luteal tissue received i.m. PGF(2)-alpha (n = 52) or PGF(2)-alpha + GnRH (n = 45) and were inseminated as described above. Conception rates were similar (39% vs 33%, respectively). In Experiment 3, cows in a large commercial dairy with (n = 93) or without (n = 420) previous reproductive problems were given i.m. 100 mug GnRH after insemination (n = 169) or were left untreated (n = 344) at repeat services (third and fourth services). Treatment with GnRH improved (P < 0.05) conception in normal (47% vs 36%) and abnormal (25% vs 12%) repeat-breeding cows. Treatment with PGF(2)-alpha alone or in conjunction with GnRH failed to further improve conception rates and only delayed intervals to rebreeding when administered during the luteal phase after the repeated estrus. The use of GnRH failed to reduce intervals from treatment to insemination or improve conception in cows with unobserved estrus compared to treatment with PGF(2)-alpha alone.     

Control of estrus in bos indicus and bos taurus heifers with prostaglandin F2 alpha

Lutalyse^*, a commercial preparation of prostaglandin F_2a was injected intramuscularly into nulliparous heifers of the German Brown, Holstein—Friesian and White Fulani cattle. Two injections, 25mg/animal each time, were given at intervals of 12 days. All the heifers were inseminated 80h after the second injection. Heifers that were cycling responded well to the treatment and had a higher conception rate than the controls.     

Synchronization of estrus following 7 or 9 day treatment with chlormadinone acetate (CAP)

Synchronization of estrus and fertility were determined in a series of 8 trials. Various levels of chlormadinone acetate (CAP) were fed for either 7 or 9 days. An injection of 5 mg of estradiol valerate and CAP was given at the start of the feeding period. In some trials estradiol 17β was injected near the end of the feeding period. In trial 1, 98% of the CAP-treated heifers were in estrus in a 5-day period, but only 46% conceived at first service compared to 80% in the non-synchronized heifers (P<.01).In trials 2 through 6, 0.25 mg estradiol 17β injected either 60 or 72 hours after the last CAP feeding reduced the interval to ovulation in heifers that ovulated. However, use of estradiol 17β reduced the number of heifers ovulating in most trials.In trials 7 and 8, estrus was effectively synchronized with either 7- or 9-day feeding of 7.5 or 10 mg of CAP daily followed by .5 mg estradiol 17β, 72 hours after the last CAP feeding. Pregnancy rates at first service varied from 21 to 45% in heifers in the synchronized groups, compared to 58% in the controls in trial 7 (P<.05). In trial 8 pregnancy rates at 1st service varied from 29 to 47% in treated heifers compared to 72% in controls (P<.01).In this series of trials, fertility was reduced from 24 to 43% with the use of CAP and estradiol valerate. Conception rates at first service were not improved by varying the length of feeding (7 or 9 days), level of CAP (7.5 or 10 mg) or by attempting to reduce the variation in ovulation time with estradiol 17β. None of the combinations of these three drugs used increased fertility in these trials.     

Effect of presynchronization using prostaglandin F2alpha and a milk-ejection test on pregnancy rate after the timed artificial insemination protocol, Ovsynch

The objective of this research was to determine if PGF2alpha-induced milk letdown (ML) is an accurate indicator of luteolysis, allowing cows to be synchronized to begin the Ovsynch protocol (GnRH-7d-PGF2alpha-2d-GnRH-24h-AI) at the most beneficial time of the estrous cycle (days 5-9), and determine if this would improve pregnancy rate (PR). Lactating Holstein cows between 55 and 70 days in milk were used to evaluate the ML test and PR after the Ovsynch protocol, when initiated on the basis of the test result (PROSYNCH). PROSYNCH cows (n = 60) had one teat cannulated to test for ML and were treated with 500 microg cloprostenol, PGF2alpha analogue (PG). Cows with ML were started on Ovsynch 10 days later, and those without started 3 days later. Cows in the control group (OVSYNCH, n = 64) were injected with physiological saline and observed for ML. This group was started on Ovsynch 10 days after saline treatment. Milk samples were collected thrice weekly to determine progesterone concentrations. ML indicated luteolysis with a sensitivity of 98% and a specificity of 60%. The positive and negative predictive values were 83 and 92%, respectively. Pregnancy rates were 48% for PROSYNCH and 52% for OVSYNCH (P = 0.72). When data from both groups were combined, PR was greater in cows that started the Ovsynch protocol in stage 2 of the estrous cycle (days 5-9, 67%) than all other stages (stage 1: days 1-4, 35%; stage 3: days 10-16, 45%; stage 4: days 17-21, 42%; P < 0.01). The proportion of animals with ovulation after GnRH#1, luteolysis after PGF2alpha, and ovulation after GnRH#2 were all greater in the PROSYNCH group (77% versus 55%, P < 0.02; 83% versus 66%, P < 0.03; 97% versus 84%, P < 0.03, respectively). Therefore, the ML test indicated luteolysis with sufficient precision to time the initiation of the Ovsynch protocol between days 5 and 9 of the cycle, however, this did not alter PR compared to starting the protocol randomly throughout the cycle. Initiating the Ovsynch protocol between days 5 and 9 of the cycle increased PR, and improved the efficacy of each injection.